Plasmodium falciparum merozoite surface protein 1 (MSP-1)

Plasmodium falciparum merozoite surface protein 1 (MSP-1) is the most abundant protein on the surface of the merozoite stage of the malaria parasite (UniProt: P04932). It is synthesized as a large 190-200 kDa precursor that undergoes sequential proteolytic processing by proteases like SUB1 and SUB2 into smaller fragments (83, 30, 38, and 42 kDa) during merozoite maturation and erythrocyte invasion (Holder et al., 1988, PubMed: 2850163). The C-terminal 19 kDa fragment (MSP-119) remains attached to the parasite membrane via a GPI anchor during entry into the host red blood cell and is a major target of protective, invasion-inhibiting antibodies (Beeson et al., 2016, PubMed: 26747113). In the context of disease, MSP-1 is essential for the blood-stage cycle of malaria, facilitating the initial attachment and subsequent entry of the parasite into erythrocytes. As a therapeutic target, MSP-1 is primarily utilized in vaccine development to elicit a host immune response; antibodies generated against MSP-1 can block the invasion process or facilitate parasite clearance through opsonization (Hill, 2011, PubMed: 21939318). Despite its promise, the high degree of genetic polymorphism in the MSP-1 gene poses a significant challenge, as it can lead to allele-specific immunity that fails to protect against diverse parasite strains (Takala et al., 2007, PubMed: 17516403). Clinical trials have evaluated various MSP-1 formulations, often combined with adjuvants like AS02, to enhance immunogenicity and provide broad-spectrum protection against Plasmodium falciparum infection.

Other names

Merozoite surface antigen 1Major merozoite surface antigenp190gp195PMMSAMSA-1

Induction of host antibodies that sterically hinder merozoite attachment to erythrocytes or inhibit the proteolytic processing of the protein required for invasion.